RedHill Biopharma raises maximum size of ATM ADS offering under H.C. Wainwright agreement

RedHill Biopharma filed a prospectus supplement raising the maximum aggregate amount of ADSs it may sell under its at-the-market offering program. The ADS sales are made from time to time under an equity distribution agreement with H.C. Wainwright entered on Feb. 3, 2025. Each ADS represents 10,000 ordinary shares. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Redhill Biopharma Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001178913-26-004765), on October 13, 2026, and is solely responsible for the information contained therein. (C)